Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTKeith Speights, The Motley FoolTue, August 25, 2026 at 11:04 AM GMT+2 4 min readImagine running a fund for 30 years, including during the aftermath of the dot-com bubble bursting and the financial crisis of 2008, without a single losing year. If you're Stanley Druckenmiller, no imagination is required. He achieved this feat for Duquesne Capital Management between 1981 and 2010, delivering an average annual return of roughly 30%.Druckenmiller no longer runs Duquesne Capital Management after deciding to close shop in 2010. However, he does manage the Duquesne Family Office, a private investment firm that handles his and his family's money.Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »With such an impressive track record, many investors understandably pay attention to which stocks Druckenmiller likes. And the billionaire continues to load up on Revolution Medicines (NASDAQ: RVMD), a biotech stock for which analysts have only modest near-term growth expectations. Does Druckenmiller know something that Wall Street doesn't?Stanley Druckenmiller. Image source: Getty Images.Don't get me wrong: Wall Street likes Revolution Medicines. Of the 22 analysts surveyed by S&P Global (NYSE: SPGI) in August, 21 rated the stock as a "buy" or "strong buy." The lone outlier recommended holding it.However, Revolution Medicines' share price has skyrocketed over the last 12 months. Analysts don't seem to think that this impressive momentum can continue. The consensus 12-month price target reflects only around 7% upside.But Druckenmiller increased his family office's stake in Revolution Medicines by 26.5% in the second quarter of 2026. He initiated a position in the biotech innovator the previous quarter.What does the super-successful investor like about Revolution? There's a simple answer to the question: the company's pipeline.Revolution Medicines awaits U.S. Food and Drug Administration (FDA) approval of daraxonrasib for previously treated metastatic pancreatic cancer. The company filed for FDA approval of the drug earlier this year after reporting positive results from a Phase 3 clinical trial. Revolution has also filed for European approval of daraxonrasib.Analysts' peak annual sales projections for the drug range from $5 billion to $7.6 billion, assuming it's approved to treat pancreatic cancer. Revolution Medicines is evaluating daraxonrasib in a late-stage study to treat non-small cell lung cancer (NSCLC).Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info